New hope for rare eye cancer: scientists test Dual-Attack treatment
NCT ID NCT07203391
Summary
This early-stage trial is testing the safety of combining two drugs, tebentafusp and roginolisib, for people with advanced uveal melanoma, a rare and aggressive eye cancer. The study aims to find the safest and most effective dose of this combination for future research. It is for a small group of patients who are already receiving one of the drugs and meet specific genetic and health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Hospital
NOT_YET_RECRUITINGMelbourne, Victoria, Australia
Contact
-
St Vincents Hospital
RECRUITINGSydney, New South Wales, 2010, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.